Skip to Content
Merck
  • Design and validation of a clinical-scale bioreactor for long-term isolated lung culture.

Design and validation of a clinical-scale bioreactor for long-term isolated lung culture.

Biomaterials (2015-03-31)
Jonathan M Charest, Tatsuya Okamoto, Kentaro Kitano, Atsushi Yasuda, Sarah E Gilpin, Douglas J Mathisen, Harald C Ott
ABSTRACT

The primary treatment for end-stage lung disease is lung transplantation. However, donor organ shortage remains a major barrier for many patients. In recent years, techniques for maintaining lungs ex vivo for evaluation and short-term (<12 h) resuscitation have come into more widespread use in an attempt to expand the donor pool. In parallel, progress in whole organ engineering has provided the potential perspective of patient derived grafts grown on demand. As both of these strategies advance to more complex interventions for lung repair and regeneration, the need for a long-term organ culture system becomes apparent. Herein we describe a novel clinical scale bioreactor capable of maintaining functional porcine and human lungs for at least 72 h in isolated lung culture (ILC). The fully automated, computer controlled, sterile, closed circuit system enables physiologic pulsatile perfusion and negative pressure ventilation, while gas exchange function, and metabolism can be evaluated. Creation of this stable, biomimetic long-term culture environment will enable advanced interventions in both donor lungs and engineered grafts of human scale.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Prosurfactant Protein B Antibody, reacts with both CT and NT, serum, Chemicon®
Pricing and availability is not currently available.